From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

GlaxoSmithKline is fortunately about so much more than the current CEO

By Chris Bailey of Financial Orbit | Sunday 2 May 2021

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I turned positive – for the first time in years and years – on GlaxoSmithKline (GSK) shares back in February here.  I noted back then that my optimism was based on much more than cheapish EV:ebit ratios and alright free cash flow generation (and the dividend paid).  As I noted again here  a few weeks back, “Hedge fund Elliott builds up multibillion-pound stake in GSK” because the anticipation that GlaxoSmithKline will split out some of its business is set to happen over the next year and this will create extra value.   

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Ariana – Surprise!

Time left: 23:02:39